Multidrug-resistant Proteus mirabilis bloodstream infections: Risk factors and outcomes

Antimicrobial Agents and Chemotherapy

Volumn 56, Issue 6, 2012, Pages 3224-3231

  Tumbarello, Mario ^a   Trecarichi, Enrico Maria ^a   Fiori, Barbara ^a   Losito, Angela Raffaella ^a   D'Inzeo, Tiziana ^a   Campana, Lara ^a   Ruggeri, Alberto ^a   Di Meco, Eugenia ^a   Liberto, Elvira ^a   Fadda, Giovanni ^a   Cauda, Roberto ^a   Spanu, Teresa ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; AZTREONAM; CEFEPIME; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEFTRIAXONE; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; LEVOFLOXACIN; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM;

ADULT; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIUM CULTURE; BACTERIUM ISOLATION; BLOODSTREAM INFECTION; CASE CONTROL STUDY; CONTROLLED STUDY; FEMALE; HEALTH CARE FACILITY; HOSPITAL ADMISSION; HUMAN; INFECTION CONTROL; MAJOR CLINICAL STUDY; MALE; MINIMUM INHIBITORY CONCENTRATION; MORTALITY; MULTIDRUG RESISTANCE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEUS MIRABILIS; RISK FACTOR; SEPTIC SHOCK; STRAIN DIFFERENCE; SURVIVAL RATE; TREATMENT FAILURE; TREATMENT OUTCOME;

AGED; ANTI-BACTERIAL AGENTS; CASE-CONTROL STUDIES; CEPHALOSPORINS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FLUOROQUINOLONES; HUMANS; KAPLAN-MEIER ESTIMATE; LOGISTIC MODELS; MALE; PROTEUS INFECTIONS; PROTEUS MIRABILIS; RETROSPECTIVE STUDIES; RISK FACTORS;

EID: 84861170226     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05966-11     Document Type: Article

References (51)

1. Baquero F, Negri MC, Morosini MI, Blàzquez J. 1998. Antibiotic-selective environments. Clin. Infect. Dis. 27(Suppl. 1):S5-S11. (Pubitemid 28375854)
2. Ben-Ami R, et al. 2009. A multinational survey of risk factors for infection with extended-spectrum beta-lactamase-producing enterobacteriaceae in nonhospitalized patients. Clin. Infect. Dis. 49:682-690.
3. Blot S, et al. 2009. Epidemiology and outcome of nosocomial bloodstream infection in elderly critically ill patients: a comparison between middle-aged, old, and very old patients. Crit. Care Med. 37:1634-1641.
4. Charlson ME, Pompei P, Ales KL, MacKenzie CR. 1987. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J. Chronic Dis. 40:373-383. (Pubitemid 17055592)
5. Chow AW, Taylor PR, Yoshikawa TT, Guze LB. 1979. A nosocomial outbreak of infections due to multiply resistant Proteus mirabilis: role of intestinal colonization as a major reservoir. J. Infect. Dis. 139:621-627. (Pubitemid 9223638)
6. Clinical and Laboratory Standards Institute. 2010. Performance standards for antimicrobial susceptibility testing; 20th informational supplement. CLSI M100-S20. Clinical and Laboratory Standards Institute, Wayne, PA.
7. Clinical and Laboratory Standards Institute. 2012. Performance standards for antimicrobial susceptibility testing; 22nd informational supplement. CLSI M100-S22. Clinical and Laboratory Standards Institute, Wayne, PA.
8. Cohen-Nahum K, Saidel-Odes L, Riesenberg K, Schlaeffer F, Borer A. 2010. Urinary tract infections caused by multi-drug resistant Proteus mirabilis: risk factors and clinical outcomes. Infection 38:41-46.
9. Cosgrove SE, Carmeli Y. 2003. The impact of antimicrobial resistance on health and economic outcomes. Clin. Infect. Dis. 36:1433-1437. (Pubitemid 36702878)
10. D'Andrea MM, et al. 2011. Evolution and spread of a multidrug-resistant Proteus mirabilis clone with chromosomal AmpC-type cephalosporinases in Europe. Antimicrob. Agents Chemother. 55:2735-2742.
11. Diekema DJ, et al. 2000. Trends in antimicrobial susceptibility of bacterial pathogens isolated from patients with bloodstream infections in the U. S. A., Canada and Latin America. Int. J. Antimicrob. Agents 13:257-271. (Pubitemid 30072742)
12. Empel J, et al. 2008. Molecular survey of β-lactamases conferring resistance to newer β-lactams in Enterobacteriaceae isolates from Polish hospitals. Antimicrob. Agents Chemother. 52:2449-2454. (Pubitemid 351923073)
13. Endimiani A, et al. 2005. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob. Agents Chemother. 49:2598-2605. (Pubitemid 40917567)
14. Giamarellos-Bourboulis EJ, et al. 2006. Multidrug resistance to antimicrobials as a predominant factor influencing patient survival. Int. J. Antimicrob. Agents 27:476-481. (Pubitemid 43767087)
15. Gilbert ND, Moellering RC, Eliopoulos GM, Chambers HF, Saag MS (ed). 2010. The Sanford guide to antimicrobial therapy. Antimicrobial Therapy, Inc., Sperryville, VA.
16. Giske CG, Monnet DL, Cars O, Carmeli Y. 2008. Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob. Agents Chemother. 52:813-821. (Pubitemid 351358357)
17. KPC carbapenemase genes on plasmids from Klebsiella strains isolated in a New York City hospital. Antimicrob. Agents Chemother. 53:1998-2004.
18. Hall RM, Collis CM. 1998. Antibiotic resistance in gram-negative bacteria: the role of gene cassettes and integrons. Drug Resist. Updat. 1:109-119.
19. Jacobsen SM, Stickler DJ, Mobley HLT, Shirtliff ME. 2008. Complicated catheter-associated urinary tract infections due to Escherichia coli and Proteus mirabilis. Clin. Microbiol. Rev. 21:26-59. (Pubitemid 351160009)
20. Kang CI, et al. 2005. Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate antimicrobial therapy on outcome. Antimicrob. Agents Chemother. 49:760-766.
21. Kaye KS, Harris AD, Samore M, Carmeli Y. 2005. The case-case-control study design: addressing the limitations of risk factor studies for antimicrobial resistance. Infect. Control Hosp. Epidemiol. 26:346-351. (Pubitemid 40545579)
22. Knaus WA, et al. 1991. The APACHE III prognostic system. Risk prediction of hospital mortality for critically ill hospitalized adults. Chest 100:1619-1636.
23. Knoll BM, et al. 2011. Reduction of inappropriate urinary catheter use at a Veterans Affairs hospital through a multifaceted quality improvement project. Clin. Infect. Dis. 52:1283-1290.
24. Kollef MH, Sherman G, Ward S, Fraser VJ. 1999. Inadequate antimicrobial treatment of infections: a risk factor for hospital mortality among critically ill patients. Chest 115:462-474. (Pubitemid 29083057)
25. Luzzaro F, et al. 2009. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management. Int. J. Antimicrob. Agents 33:328-333.
26. Luzzaro F, et al. 2011. Prevalence and epidemiology of microbial pathogens causing bloodstream infections: results of the OASIS multicenter study. Diagn. Microbiol. Infect. Dis. 69:363-369.
27. Magiorakos AP, et al. 2011. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin. Microbiol. Infect. doi:10.1111/j.1469-0691.2011.03570.x.
28. March A, et al. 2010. Colonization of residents and staff of a long-term-care facility and adjacent acute-care hospital geriatric unit by multiresistant bacteria. Clin. Microbiol. Infect. 16:934-944.
29. Migliavacca R, et al. 2007. Molecular epidemiology of ESbetaL producing P. mirabilis strains from a long-term care and rehabilitation facility in Italy. New Microbiol. 30:362-366. (Pubitemid 47264907)
30. Nicolas-Chanoine MH, Jarlier V, La Collégialé de Bactériologie-Virologie-Hygiène Hospitalière de l'Assistance Publique Hôpitaux de Paris France. 2008. Extended-spectrum beta-lactamases in long-termcare facilities. Clin. Microbiol. Infect. 14(Suppl. 1):111-116.
31. Pagani L, et al. 2002. Emerging extended-spectrum β-lactamases in Proteus mirabilis. J. Clin. Microbiol. 40:1549-1552. (Pubitemid 34279938)
32. Paterson DL, et al. 2001. Outcome of cephalosporin treatment for serious infections due to apparently susceptible organisms producing extendedspectrum beta-lactamases: implications for the clinical microbiology laboratory. J. Clin. Microbiol. 39:2206-2212. (Pubitemid 32531482)
33. Paterson DL. 2004. "Collateral damage" from cephalosporin or quinolone antibiotic therapy. Clin. Infect. Dis. 38(Suppl. 4):S341-S345. (Pubitemid 38669889)
34. Perilli M, et al. 2002. Characterization of a new extended-spectrum beta-lactamase (TEM-87) isolated in Proteus mirabilis during an Italian survey. Antimicrob. Agents Chemother. 46:925-928. (Pubitemid 34157692)
35. Qureshi ZA, et al. 2011. Risk factors and outcome of extended-spectrum beta-lactamase-producing Enterobacter cloacae bloodstream infections. Int. J. Antimicrob. Agents 37:26-32.
36. Rodríguez-Baño J, Navarro MM, Retemar P, Picón E, Á. Pasqualand Extended-Spectrum Beta-Lactamases-Red Española de Investigación en Patologia Infecciosa/Grupo de Estudio de Infección Hospitaliaria Group. 2012. β-Lactam/β-lactam inhibitor combinations for the treatment of bacteremia due to extended-spectrum β-lactamase-producing Escherichia coli: a post hoc analysis of prospective cohorts. Clin. Infect. Dis. 54:167-174.
37. Russell JA. 2006. Management of sepsis. N. Engl. J. Med. 355:1699-1713. (Pubitemid 44583960)
38. Sader HS, Jones RN, Andrade-Baiocchi S, Biedenbach DJ. 2002. Four-year evaluation of frequency of occurrence and antimicrobial susceptibility patterns of bacteria from bloodstream infections in Latin American medical centers. Diagn. Microbiol. Infect. Dis. 44:273-280. (Pubitemid 35454102)
39. Spanu T, et al. 2002. Occurrence of extended-spectrum beta-lactamases in members of the family Enterobacteriaceae in Italy: implications for resistance to beta-lactams and other antimicrobial drugs. Antimicrob. Agents Chemother. 46:196-202. (Pubitemid 34031625)
40. Spanu T, et al. 2006. Evaluation of the new VITEK 2 extended-spectrum beta-lactamase (ESBL) test for rapid detection of ESBL production in Enterobacteriaceae isolates. J. Clin. Microbiol. 44:3257-3262. (Pubitemid 44413761)
41. Tsakris A, et al. 2007. Transmission in the community of clonal Proteus mirabilis carrying VIM-1 metallo-beta-lactamase. J. Antimicrob. Chemother. 60:136-139. (Pubitemid 47073287)
42. Tumbarello M, et al. 2006. Bloodstream infections caused by extended-spectrum-beta-lactamase-producing Klebsiella pneumoniae: risk factors, molecular epidemiology, and clinical outcome. Antimicrob. Agents Chemother. 50:498-504. (Pubitemid 43190958)
43. Tumbarello M, et al. 2007. Predictors of mortality in patients with bloodstream infections caused by extended-spectrum-beta-lactamaseproducing Enterobacteriaceae: importance of inadequate initial antimicrobial treatment. Antimicrob. Agents Chemother. 51:1987-1994. (Pubitemid 46903084)
44. Tumbarello M, et al. 2008. Bloodstream infections caused by extended-spectrum-beta-lactamase producing Escherichia coli: risk factors for inadequate initial antimicrobial therapy. Antimicrob. Agents Chemother. 52:3244-3252.
45. Tumbarello M, et al. 2010. Costs of bloodstream infections caused by Escherichia coli and influence of extended-spectrum-beta-lactamase production and inadequate initial antibiotic therapy. Antimicrob. Agents Chemother. 54:4085-4091.
46. Tumbarello M, et al. 2011. Multidrug-resistant Pseudomonas aeruginosa bloodstream infections: risk factors and mortality. Epidemiol. Infect. 13:1-10.
47. Tumbarello M, et al. 2011. Identifying patients harboring extended-spectrum-beta-lactamase-producing Enterobacteriaceae on hospital admission: derivation and validation of a scoring system. Antimicrob. Agents Chemother. 55:3485-3490.
48. Urban C, et al. 2010. Identification of CTX-M beta-lactamases in Escherichia coli from hospitalized patients and residents of long-term care facilities. Diagn. Microbiol. Infect. Dis. 66:402-406.
49. Wang P, et al. 2011. Susceptibility of ESBL-producing Enterobacteriaceae with the new CLSI breakpoints. J. Clin. Microbiol. 49:3127-3131.
50. Watanakunakorn C, Perni SC. 1994. Proteus mirabilis bacteremia: a review of 176 cases during 1980-1992. Scand. J. Infect. Dis. 26:361-367. (Pubitemid 24245120)
51. Wilson J, et al. 2011. Trends among pathogens reported as causing bacteraemia in England, 2004-2008. Clin. Microbiol. Infect. 17:451-458.